Understanding Paediatric Traumatic Brain Injury in the UK

Traumatic brain injury (TBI) in children, often referred to as paediatric traumatic brain injury (pTBI), represents a significant health challenge across the United Kingdom. Defined as damage to the brain caused by external mechanical force, pTBI can result from falls, road traffic accidents, assaults, or sports-related incidents. Unlike adults, children's developing brains are particularly vulnerable, with injuries potentially leading to long-term cognitive, behavioural, and physical impairments. In the UK, moderate to severe pTBI has an incidence rate of approximately 14 per 100,000 person-years, affecting thousands of children annually. Mortality rates for severe cases range from 3% to 35%, depending on factors like injury severity and access to timely care, while survivors often face lifelong rehabilitation needs.

The economic and emotional toll is immense, with families navigating complex recovery paths. Early intervention is crucial, as secondary brain injury from swelling—increased intracranial pressure (ICP)—can exacerbate damage. ICP, the pressure inside the skull exerted by the brain tissue, blood, and cerebrospinal fluid, if elevated, compresses brain structures, reducing blood flow and oxygen delivery. Current management relies on monitoring and controlling this pressure to prevent further harm.

Current Guidelines for Managing ICP in Paediatric TBI

Paediatric TBI management in the UK draws from international standards like the Brain Trauma Foundation (BTF) Guidelines for Pediatric Severe TBI, Third Edition, which recommend treating ICP above 20 mmHg. This threshold, a Level II recommendation, stems largely from adult data extrapolated to children, as paediatric-specific evidence has been limited. The Royal College of Paediatrics and Child Health (RCPCH) and National Institute for Health and Care Excellence (NICE) provide complementary guidance on initial assessment, emphasizing CT imaging and transfer to specialist centres for severe cases (Glasgow Coma Scale ≤8).

Treatment tiers include hyperosmolar therapy (e.g., mannitol or hypertonic saline), sedation, hyperventilation, and surgical decompression if ICP remains refractory. Cerebral perfusion pressure (CPP)—mean arterial pressure minus ICP—is targeted at 40-50 mmHg or higher for older children. However, fixed thresholds may not account for individual variability in cerebrovascular autoregulation (CA), the brain's ability to maintain stable blood flow despite pressure changes. Disruptions in CA, measured by the pressure reactivity index (PRx), correlate with worse outcomes, prompting calls for personalised approaches.

The STARSHIP Study: A Groundbreaking UK Collaboration

The Studying Trends of Auto-Regulation in Severe Head Injury in Paediatrics (STARSHIP) study marks a pivotal advancement in UK paediatric neurocritical care research. Led by Dr Shruti Agrawal, a consultant paediatric intensivist at Cambridge University Hospitals NHS Foundation Trust (CUH) and affiliated with the University of Cambridge, STARSHIP is the UK's first prospective multicentre observational study on severe pTBI. Spanning 10 Paediatric Intensive Care Units (PICUs) from 2018 to 2024, it recruited 135 children under 16 years with severe TBI requiring invasive ICP and arterial blood pressure (ABP) monitoring.

Funded by Addenbrooke’s Charitable Trust, Action Medical Research for Children, and supported by the National Institute for Health and Care Research (NIHR), the study generated a high-resolution database of physiological waveforms (≥100 Hz), clinical data, and 12-month outcomes using the Glasgow Outcome Scale Extended-Pediatrics (GOSE-Peds). Collaborators included leading institutions like Great Ormond Street Hospital, Birmingham Children’s Hospital, and University of Oxford. Initial findings on PRx were published in eClinicalMedicine (The Lancet) in February 2025, validating PRx thresholds (0.0 for favourable outcomes, 0.5 for mortality).

Landmark JAMA Pediatrics Findings: Lower ICP Thresholds

A secondary analysis from the STARSHIP database, published in JAMA Pediatrics as “Intracranial Pressure Treatment Thresholds in Pediatric Traumatic Brain Injury,” has ignited global discussion. It revealed that sustained ICP elevations above 14-15 mmHg are strongly associated with poor long-term functional outcomes, independent of injury severity (e.g., GCS, Injury Severity Score) and treatment intensity. Children maintaining ICP below this range showed significantly better recovery at 12 months.

This challenges the 20 mmHg benchmark, suggesting children's brains tolerate less pressure elevation due to unique physiology—thinner skulls, higher cerebral blood volume, and immature autoregulation. Dr Agrawal noted: “Our findings suggest that clinically relevant treatment thresholds in children with TBI may be lower than the current 20 mmHg benchmark.” The prospective design and multicentre nature strengthen these insights, positioning STARSHIP as a foundational resource for future analyses.Read the CUH announcement.

Mechanisms Behind ICP and Outcomes in Children

Step-by-step, elevated ICP impairs cerebral blood flow: (1) Brain swelling post-impact increases volume; (2) Skull rigidity elevates pressure; (3) If >14-15 mmHg sustained, it exceeds autoregulatory limits, causing ischaemia or herniation. STARSHIP's PRx data showed elevated PRx (>0) alongside high ICP predicts unfavourable outcomes (OR 1.28, p=0.024 after adjustments). CPPopt, the ideal CPP minimising PRx, rose with age (61 mmHg for 0-2 years, 67 mmHg for ≥8 years), underscoring age-specific targets.

Real-world example: A 10-year-old road traffic accident victim in STARSHIP maintained ICP <15 mmHg via early hypertonic saline, achieving favourable GOSE-Peds (good recovery). Contrastingly, sustained peaks >15 mmHg correlated with disability or death.

Photo by Markus Winkler on Unsplash

Implications for UK Clinical Practice and Guidelines

These findings urge revision of BTF and UK protocols. NICE head injury guidance (NG232) focuses on assessment, but ICP management could integrate dynamic PRx/LLA monitoring for personalised CPP > patient-specific lower limit of autoregulation (LLA), often >50 mmHg. PICUs like CUH are piloting lower thresholds cautiously, balancing risks of over-treatment (e.g., hypotension from osmotherapy).

Stakeholder views: Paediatric intensivists advocate prospective RCTs; neurosurgeons highlight surgical synergies. For families, earlier stabilisation could halve disability rates. BTF Pediatric Guidelines may update soon, influencing RCPCH standards.

Expert Perspectives from UK Researchers

Dr Agrawal's team, including University of Cambridge's Prof Peter Hutchinson and UCL's Prof Marek Czosnyka (PRx pioneer), emphasises multimodal monitoring. “STARSHIP offers a unique opportunity for ongoing research,” says Agrawal. Collaborations across Manchester, Oxford, and Sheffield underscore higher education's role in translational neurocritical care. This positions UK universities as leaders, fostering PhD/postdoc opportunities in paediatric neurosciences.

Real-World Case Studies and Recovery Journeys

Consider 'Alex,' a 7-year-old from Leeds PICU in STARSHIP: Post-fall TBI with initial ICP 22 mmHg, aggressive management lowered it to 13 mmHg; he returned to school with minor cognitive therapy after 6 months. Conversely, delayed control in another case led to vegetative state. UK stats: 70% survivors in STARSHIP had favourable outcomes when ICP controlled early. Rehabilitation at centres like The Children's Trust integrates therapy, education, and family support, with 84% good recovery at discharge in some cohorts.

Challenges in Paediatric Neurocritical Care Research

• Rarity: Severe pTBI low incidence limits single-centre studies; STARSHIP's multicentre model overcomes this.
• Data Quality: High-resolution monitoring artifacts require advanced processing (ICM+ software).
• Ethics/Funding: Invasive monitoring in children demands rigorous consent; NIHR/charity support vital.
• Translation: Observational data needs RCTs for causality.

Solutions: Shared databases like STARSHIP enable big data AI analyses for predictive models.

Future Outlook: Personalised Medicine and UK Leadership

STARSHIP paves the way for phase II trials on ICP 14-15 mmHg targets, dynamic CPPopt, and AI-driven PRx alerts. UK investments in NIHR Cambridge BRC position universities for global impact. Actionable insights: Train more paediatric neurointensivists; integrate PRx in PICU protocols by 2030. For academics, opportunities abound in grants like UKRI for pTBI innovation. STARSHIP PRx paper in eClinicalMedicine.

Optimised ICP control could transform outcomes, reducing UK's pTBI burden and enhancing child health equity.

Photo by Karl Solano on Unsplash

Stakeholder Impacts and Broader Societal Benefits

NHS trusts gain evidence for resource allocation; universities attract talent via research jobs. Parents benefit from proactive care, potentially averting £millions in lifelong support. Multi-perspective: Policymakers eye guideline updates; educators incorporate into curricula. STARSHIP exemplifies collaborative higher education driving clinical change.